by Nina DiPrimio | Mar 26, 2018 | UDN |
This is my first post in a few months, and a lot has changed at Perlara since then! We doubled in size, expanding and creating more research teams, and launched multiple PerlQuests in addition to the original PerlQuest for NGLY1 deficiency. Our latest news is that we...
by Nina DiPrimio | Jan 12, 2017 | Perlara science |
Well it has been a little while since I wrote a post, and a lot has happened since then, which I am sure you read about in our blogs and tweets. We changed our company name, partnered with Novartis and started partnering with patient groups to engineer our organisms...
by Nina DiPrimio | Jul 5, 2016 | Uncategorized |
I have been anxiously awaiting this moment, the time in which I can write a blog post on our pilot study with Vium, formerly Mousera. Perlstein Lab had an opportunity to work with Vium starting about one year prior to their out-of-stealth launch, and I am itching to...
by Nina DiPrimio | May 17, 2016 | Uncategorized |
It has been a while since you have heard from me. We are deep in post screen characterization of our NPC hits so I thought I would take a step back to the beginning to discuss NPC disease biology. We focused a bit on the cholesterol and lipid metabolism aspects of...
by Nina DiPrimio | Dec 14, 2015 | Uncategorized |
To continue on the theme of understanding your compound of interest’s mechanism of action, let’s discuss target identification (ID). You have just completed your screen and found a hit, but now you want to learn more about why it is a hit. As mentioned before,...
